Association between inflammatory mediators and the fibrinolysis system in infectious pleural effusions
- PMID: 12826021
- DOI: 10.1042/CS20030115
Association between inflammatory mediators and the fibrinolysis system in infectious pleural effusions
Abstract
The response of the fibrinolytic system to inflammatory mediators in empyema and complicated parapneumonic pleural effusions is still uncertain. We prospectively analysed 100 patients with pleural effusion: 25 with empyema or complicated parapneumonic effusion, 22 with tuberculous effusion, 28 with malignant effusion and 25 with transudate effusion. Inflammatory mediators, tumour necrosis factor-alpha (TNF-alpha), interleukin-8 (IL-8) and polymorphonuclear elastase, were measured in serum and pleural fluid. Fibrinolytic system parameters, plasminogen, tissue-type plasminogen activator (t-PA) and urokinase PA, PA inhibitor type 1 (PAI 1) and PAI type 2 concentrations and PAI 1 activity, were quantified in plasma and pleural fluid. The Wilcoxon signed-rank test was used to compare plasma and pleural values and to compare pleural values according to the aetiology of the effusion. The Pearson correlation coefficient was used to assess the relationship between fibrinolytic and inflammatory markers in pleural fluid. Significant differences were found between pleural and plasma fibrinolytic system levels. Pleural fluid exudates had higher fibrinolytic levels than transudates. Among exudates, tuberculous, empyema and complicated parapneumonic effusions demonstrated higher pleural PAI levels than malignant effusions, whereas t-PA was lowest in empyema and complicated parapneumonic pleural effusions. PAI concentrations correlated with TNF-alpha, IL-8 and polymorphonuclear elastase when all exudative effusions were analysed, but the association was not maintained in empyema and complicated parapneumonic effusions. A negative association found between t-PA and both IL-8 and polymorphonuclear elastase in exudative effusions was strongest in empyema and complicated parapneumonic effusions. Blockage of fibrin clearance in empyema and complicated parapneumonic effusions was associated with both enhanced levels of PAIs and decreased levels of t-PA.
Comment in
-
Can inflammatory mediators affect fibrinolysis in the pleural space?Clin Sci (Lond). 2003 Nov;105(5):541-3. doi: 10.1042/CS20030242. Clin Sci (Lond). 2003. PMID: 12868957
Similar articles
-
Cytokines and fibrinolytic enzymes in tuberculous and parapneumonic effusions.Clin Immunol. 2005 Aug;116(2):166-73. doi: 10.1016/j.clim.2005.03.015. Clin Immunol. 2005. PMID: 15897010
-
Metalloproteinases and tissue inhibitors of metalloproteinases in exudative pleural effusions.Eur Respir J. 2005 Jan;25(1):104-9. doi: 10.1183/09031936.04.00010504. Eur Respir J. 2005. PMID: 15640330
-
Proinflammatory cytokines, transforming growth factor-beta1, and fibrinolytic enzymes in loculated and free-flowing pleural exudates.Chest. 2005 Aug;128(2):690-7. doi: 10.1378/chest.128.2.690. Chest. 2005. PMID: 16100155
-
Intra-pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult parapneumonic effusions and empyema.Cochrane Database Syst Rev. 2019 Oct 30;2019(10):CD002312. doi: 10.1002/14651858.CD002312.pub4. Cochrane Database Syst Rev. 2019. PMID: 31684683 Free PMC article.
-
Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.Dan Med Bull. 1993 Sep;40(4):383-408. Dan Med Bull. 1993. PMID: 8222763 Review.
Cited by
-
Pneumonia and empyema: causal, casual or unknown.J Thorac Dis. 2015 Jun;7(6):992-8. doi: 10.3978/j.issn.2072-1439.2015.04.36. J Thorac Dis. 2015. PMID: 26150912 Free PMC article. Review.
-
Targeting the PAI-1 Mechanism with a Small Peptide Increases the Efficacy of Alteplase in a Rabbit Model of Chronic Empyema.Pharmaceutics. 2023 May 14;15(5):1498. doi: 10.3390/pharmaceutics15051498. Pharmaceutics. 2023. PMID: 37242740 Free PMC article.
-
Precision targeting of the plasminogen activator inhibitor-1 mechanism increases efficacy of fibrinolytic therapy in empyema.Physiol Rep. 2021 May;9(9):e14861. doi: 10.14814/phy2.14861. Physiol Rep. 2021. PMID: 33991465 Free PMC article.
-
Clinical importance of angiogenic cytokines, fibrinolytic activity and effusion size in parapneumonic effusions.PLoS One. 2013;8(1):e53169. doi: 10.1371/journal.pone.0053169. Epub 2013 Jan 7. PLoS One. 2013. PMID: 23308155 Free PMC article.
-
Involvement of Heparanase in Empyema: Implication for Novel Therapeutic Approaches.J Clin Cell Immunol. 2015 Feb;6(1):290. doi: 10.4172/2155-9899.1000290. J Clin Cell Immunol. 2015. PMID: 26005591 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources